Celgene alliance gives VentiRx funding and expertise - and maybe a new owner
This article was originally published in Scrip
Executive Summary
When it came time to evaluate partners for its toll-like receptor 8 (TLR8) agonist VTX-2337, privately-held VentiRx Pharmaceuticals went with Celgene, because of the public company's success in developing cancer therapies and its growing interest in both immunotherapies and the treatment of solid tumours.
You may also be interested in...
Celgene's Partnered Pipeline Delivers Successes And Setbacks
Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.
Finance Watch: 2021 Biopharma VC Funding Tops Full-Year 2020 Total
Private Company Edition: The industry raised $28bn in venture capital through the third quarter, breaking the record $27.4bn raised last year. Also, big pharmas backed a start-up lab in Israel, plus mega-rounds for CinCor Pharma ($143m) and Rectify Pharmaceuticals ($100m), while Cerecin raises $40m.
Biogen Seeking A Path Forward After Phase III Tofersen Study Fails In ALS
The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.